NYSE:LLYPharmaceuticals
Eli Lilly (LLY) Could Be 19% Undervalued After Novo Nordisk Lawsuit
Novo Nordisk’s lawsuit over obesity and diabetes drug advertising has pulled Eli Lilly (LLY) further into the spotlight and raised fresh questions about how this legal challenge could intersect with the stock’s recent strength.
See our latest analysis for Eli Lilly.
Against this backdrop, Eli Lilly’s share price has recently eased about 1% over 30 days after reaching record territory. Shorter term momentum remains positive with a 90 day share price return of 37.75% and a 1 year total...